The Dyspnea market report also offers comprehensive insights into the Dyspnea market size, share, Dyspnea epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Dyspnea market size growth forward.
Some of the key highlights from the Dyspnea Market Insights Report:
-
Several key pharmaceutical companies, including United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Relief Therapeutics, AstraZeneca, GlaxoSmithKline, Novartis AG, Boehringer Ingelheim, and others, are developing novel products to improve the Dyspnea treatment outlook.
-
In October 2024, the FDA approved Dupixent as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by eosinophilic inflammation. This marks the first biologic therapy approved for COPD in the U.S., aiming to reduce exacerbations and improve lung function.
-
Approved by the FDA in June 2024, Ohtuvayre is an inhaled maintenance therapy for adults with COPD. As a first-in-class dual inhibitor of phosphodiesterase 3 and 4, it offers both bronchodilator and anti-inflammatory effects, enhancing lung function and reducing symptom exacerbations.
-
In March 2024, the FDA approved sotatercept for treating PAH in adults. This novel therapy improves exercise capacity and reduces the risk of clinical worsening events by targeting activin signaling pathways, offering a new approach to managing PAH-related dyspnea.
-
In August 2024, the FDA granted Breakthrough Therapy Designation to Tezspire as an add-on maintenance treatment for patients with moderate to very severe COPD characterized by an eosinophilic phenotype. This designation facilitates the development and review of therapies that may offer substantial improvements over existing treatments.
-
As per DelveInsight analysis, the Dyspnea market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Dyspnea Market Landscape
Dyspnea Overview
Dyspnea is the medical term for shortness of breath or difficulty breathing. It can feel like a tightness in the chest, a sensation of suffocation, or an increased effort to breathe.
Do you know the treatment paradigms for different countries? Download our Dyspnea Market Sample Report
Dyspnea Epidemiology Insights
-
Dyspnea is notably prevalent among oncology patients, particularly those with advanced stages of cancer.
Dyspnea Epidemiology Segmentation
DelveInsight’s Dyspnea market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Dyspnea historical patient pools and forecasted Dyspnea patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Dyspnea Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
-
Dyspnea Prevalence
-
Age-Specific Dyspnea Prevalence
-
Gender-Specific Dyspnea Prevalence
-
Diagnosed and Treatable Cases of Dyspnea
Visit for more @ Dyspnea Epidemiological Insights
Dyspnea Market Outlook
The global dyspnea treatment market is experiencing significant growth, driven by the increasing prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and pneumonia.
Key Factors Driving Dyspnea Market Growth:
-
Rising Respiratory Disorders: The increasing incidence of conditions like COPD and asthma contributes significantly to the demand for dyspnea treatments.
-
Air Pollution: Elevated pollution levels exacerbate respiratory issues, leading to a higher prevalence of dyspnea.
-
Aging Population: An older demographic is more susceptible to respiratory ailments, thereby increasing the need for effective dyspnea management.
The dyspnea treatment market is poised for substantial growth in the coming years, driven by factors such as the rising prevalence of respiratory disorders, environmental challenges, and demographic shifts. Ongoing advancements in treatment modalities and increased healthcare investments are expected to further propel market expansion.
Dyspnea Key Companies
-
United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Relief Therapeutics, AstraZeneca, GlaxoSmithKline, Novartis AG, Boehringer Ingelheim, and others
For more information, visit Dyspnea Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Dyspnea Market Report:
-
11 Years Forecast
-
7MM Coverage
-
Descriptive overview of Dyspnea, causes, signs and symptoms, diagnosis, treatment
-
Comprehensive insight into Dyspnea epidemiology in the 7MM
-
Dyspnea marketed and emerging therapies
-
Dyspnea companies
-
Dyspnea market drivers and barriers
Table of Contents:
1 Dyspnea Market Key Comprehensive Insights
2 Dyspnea Market Report Introduction
3 Competitive Intelligence Analysis for Dyspnea
4 Dyspnea Market Analysis Overview at a Glance
5 Executive Summary of Dyspnea
6 Dyspnea Epidemiology and Market Methodology
7 Dyspnea Epidemiology and Patient Population
8 Dyspnea Patient Journey
9 Dyspnea Treatment Algorithm, Dyspnea Current Treatment, and Medical Practices
10 Key Endpoints in Dyspnea Clinical Trials
11 Dyspnea Marketed Therapies
12 Dyspnea Emerging Therapies
13 Dyspnea: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Dyspnea
16 Dyspnea Market Key Opinion Leaders Reviews
18 Dyspnea Market Drivers
19 Dyspnea Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Dyspnea Epidemiology 2032
DelveInsight’s “Dyspnea – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Dyspnea epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Dyspnea Pipeline 2024
“Dyspnea Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dyspnea market. A detailed picture of the Dyspnea pipeline landscape is provided, which includes the disease overview and Dyspnea treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/